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Summary
Objective: Vitamin A derivatives are widely used therapeutic agents for the treatment of dermatological and rheumatological disorders.
Long-standing administration of these drugs, in turn, causes skeletal changes including ossification of ligaments, premature fusion of
epiphyses and abnormalities of modeling. Recent in vitro experiments have further suggested that retinoid treatment of cultured
chondrocytes may cause apoptotic cell death. The present study aims to address detailed cartilage changes associated with in vivo
administration of vitamin A derivatives.
Methods: Retinyl acetate was administrated to experimental mice, C3H-Heston, for more than 12 months. Modified morphometry on the
articular cartilage and fluorescent labeling of the subchondral bone were carried out to address the changes in the articular cartilage and
subchondral bone. In order to address the detailed chondrocytes phenotypes, electron microscopy was carried out. Since findings of these
studies suggested that biological properties of the cartilage matrix might be altered, the present study also immunolocalized functional matrix
molecules, type I collagen and osteoblast-stimulating factor-1 (OSF-1).
Results: Histomorphometry demonstrated that retinoid administration lead to progressive atrophy of the articular cartilage with concomitant
proliferation of subchondral bone. Furthermore, detailed light and electron microscopy suggested that the subchondral bone proliferates into
the degenerating cartilage. The affected articular cartilage also resembled that of osteoarthritis in terms of ectopic type I collagen production.
Furthermore, the affected articular cartilage produced a developmentally regulated matrix molecule, osteoblast-stimulating factor-1 (OSF-1)
that is normally expressed in both the fetal cartilage and the epiphyseal growth plate cartilage but not in the articular cartilage.
Conclusion: The present results indicate that the systemic retinoid administration may alter the biological properties of the articular
cartilage. © 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Synthetic derivatives of vitamin A are widely used therapeu-
tic agents for the treatment of dermatological (cystic acne
and keratotic skin disorders) and rheumatological (psoriatic
arthritis) diseases, and are currently being tested for tumor-
prophylactic effects in the hope of preventing cancer1.
Long-standing administration of these drugs, however, has
been shown to cause ectopic bone formation around the
joints2,3. The classical observations that excessive intake
of the naturally occurring vitamin A gives rise to ectopic968bone formation4,5 also provide a rationale to the skeletal
changes associated with the systemic retinoid therapy.
Recent in vitro experiments have demonstrated that
retinoic acid, a vitamin A derivative, accelerates the pro-
grammed cell death (apoptosis) of articular chondrocytes.
The cellular process leading to the apoptotic cell death of
chondrocytes appears to shear the common molecular
mechanism to that of the age-associated cell death of
articular chondrocytes6,7. These studies suggest that
degeneration of articular cartilage could be another import-
ant skeletal change induced by the systemic retinoid
therapy. To date, however, there have been hardly any
in vivo experiments addressing the cartilage changes that
appear during long-standing administration of vitamin A
derivatives. In the present study, retinyl acetate, a synthetic
derivative of vitamin A, was given to experimental mice.
Modified morphometry on the articular cartilage and double
fluorescent labeling of the subchondral bone was pre-
liminarily carried out in order to delineate the cartilage and
subchondral bone phenotypes of the treated mice.
The preliminary study by the morphometry demonstrated
progressive atrophy of the cartilage and the proliferation of
subchondral bone into the degenerating cartilage. These
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ANIMALS AND SAMPLES
The present study used total 60 male C3H-Heston mice
(4 weeks old, Charles River Japan, Yokohama, Japan).
The mice were divided into three groups according to the
amounts of retinyl acetate (Rac) in the diet (Table 1). The
diet for the high dose group contained 2850 international
units (IU) of Rac in 100 g of standard powdered mice chow
(Oriental Bio, Tokyo, Japan). The diet for the intermediate
dose group contained 400 IU Rac/100 g. The diet for the
control group did not contain Rac but contained natural
forms of vitamin A, the total amount of which is approxi-
mately 100 IU/100 g. The mice in each group consumed
mean of 20 g of diet/week, corresponding to a daily intake
of approximately 81.4 IU Rac+2.9 IU natural forms of vita-
min A (high dose group), 14.3 IU Rac+2.9 IU natural vita-
min A (intermediate dose group), and 2.9 IU vitamin A
(control group). Water was given ad libitum. The animals
were sacrificed at 6, 9, and 12 months after the beginning
of the Rac administration (six, seven, and seven animals,
respectively). After the overdose injection of pentobarbital,
the animals were perfused through the left ventricle with
0.01 M phosphate buffered saline (PBS), and were fixed
with 0.5% glutaraldehyde and 4% paraformaldehyde in
0.1 M.RADIOLOGICAL ANALYSES
Contact radiographs were made immediately after the
excision of samples (Softex CMB-2, MFG&EXP. Softex Co.
Ltd., Tokyo, Japan). Longitudinal lengths of the ossified
lesions at the suprapatellar (sp) and Achilles (ac) tendonsFig. 1. Contact radiographs showing juxtaarticular ossification. (a),
(c) and (e) exemplify the radiographs of ankle joint; (b), (d), and (f)
exemplify those of knee joint. Note the ossification at the tendon
insertion and their extension along the tendons. ac: length of
Achilles tendon, and sp: length of suprapatellar tendon. (after
12-month administration).Fig. 2. Length of juxtaarticular ossification. Longitudinal length of
the ossified lesion at the suprapatellar (sp) and Achilles (ac)
tendons was measured and presented as mean mm±S.E.M. Bars
represent the measured values of 0.38±0.09 (mm) and 0.17±0.08
for the suprapatellar (sp) and Achilles (ac) tendons of normal
control group, 0.91±0.78 and 0.42±0.21 for intermediate group,
and 1.09±0.16 and 1.52±0.69 for the high dose group, respect-
ively. Note the dose-dependent proliferation of the ossified lesion in
the Rac-administrated animal.phenotypes are likely to be associated with altered biologi-
cal properties of the articular cartilage. Articular chondro-
cytes normally produce type II collagen as the major
constituent of cartilage, but do not produce type I collagen
except for the diseased chondrocytes of osteoarthritis (OA)
producing type I collagen. The affected articular cartilage
resembled the osteoarthritic cartilage in terms of ectopic
type I collagen production. Furthermore, the affected articu-
lar cartilage produces a developmentally regulated matrix
molecule, osteoblast-stimulating factor-1 (OSF-1) that is
normally expressed in the epiphyseal growth plate cartilage
but not in the articular cartilage. The present results indi-
cate that systemic retinoid administration gives rise to
articular cartilage atrophy with increased subchondral bone
deposition. The suggested roles of the ectopically
expressed matrix molecules give insights to the patho-
genesis of cartilage changes occurring during systemic
administration of retinoids.Table 1
Diet of the animals
Mixture of natural
forms vitamin A
(in 100 g diet)
Retinyl acetate
(in 100 g diet)
Normal control group 100 IU 0 IU
Intermediate dose group 100 IU 400 IU
High dose group 100 IU 2850 IU
Standard powdered mice chow® (Oriental Bio, Tokyo, Japan),
ordinary experimental mice diet, contains a number of natural
vitamin A forms, the total amount of which correspond to vitamin A
of 100 international unit (IU) in 100 g diet. The diet for high dose
group contained 2850 IU retinyl acetate in addition to the 100 IU
natural vitamin A. The diet for intermediate group contained 400 IU
retinyl acetate in addition to the 100 IU natural vitamin A.
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Undecalcified and decalcified sections (5 m) were
made from the proximal end of tibia following the pro-
tocol described elsewhere8. Morphometry was performed
within a defined field [2.0 mm×2.0 mm, see Fig. 4(a), (b)]
using digital image analyzer (Image-Pro Plus, Media
Cybernetics, CA, U.S.A.). Trabecular bone volume (BV/TV)
was measured to assess the subchondral bone prolifer-
ation. Fluorescent double labeling was performed following
the protocol described elsewhere9 with calcein injected
twice at 6 months old (7-day interval, N=6 per group). The
following parameters were measured to estimate quantita-
tively the increase of bone formation. Mineral apposition
rate (MAR) is calculated by dividing the distance of the
double fluorescent strands by the time interval (m/day).
Osteoid surface (OS) is obtained dividing the sum of the
length of double strand and half-length of single strand by
the bone surface perimeter [(dLS+sLS/2)/BS]. Bone forma-
tion rate (BFR) is obtained by multiplying MAR by MS. The
value is presented on a year basis (m3/m2/year). The
nomenclatures and the formulae followed the recommen-
dations by the American Society for Bone and MineralResearch10. Reproducibility of each method is provided
elsewhere8–10.MORPHOMETRY OF ARTICULAR CARTILAGE
Proteoglycan staining with low pH toluidine blue (pH:
5.0) enabled differentiation of the hyaline cartilage and the
mineralized cartilage [see Fig. 3(c), (d)]. The articular
cartilage area measured within the defined field
[2.0 mm×2.0 mm, see Fig. 4(a),(b)] represented the vol-
ume of articular cartilage and was presented as mean
m±S.E.M.Fig. 3. Subchondral bone hypertrophy and cartilage atrophy after
12-month treatment with Rac. (a) The knee joint of the control
animal demonstrates the normal thickness of the subchondral and
trabecular bone. (b) Knee joint of the high Rac dose animal
demonstrates the thickened subchondral bone trabeculae. (A, B;
hematoxylin & eosine micrograph, ×30, arrows indicating the
thickness of trabecular bone: tb). (c) The knee joint of the control
animal. Proteoglycan staining of the articular cartilage differenti-
ates the hyaline cartilage (hc) and the mineralized cartilage (mc).
Note the smooth surface of the cartilage. sb:subchondral bone. (d)
The joint structure of the Rac-administrated animal is character-
ized by proliferated subchondral bone, disappearance of the
mineralized cartilage and atrophy of hyaline cartilage. Note
the rough surface of the cartilage. (C, D; acidic toluidin blue
micrograph, ×200).Fig. 4. Modified morphometry for the articular cartilage and
subchondral bone. (a) The defined field (2.0 mm×2.0 mm) for
bone and cartilage morphometry. (b) The upper edge of the field is
placed on the upper edge of the articular surface. The area of the
articular cartilage (m 2) represents the cartilage volume. The
nomenclature and formulae for bone morphometry followed the
recommendations by the American Society for Bone and Mineral
Research10.IMMUNOHISTOCHEMISTRY
Samples from the proximal end of tibia were decalcified
by 4% EDTA in cacodylate buffer (pH 7.3), and cryostat
sections were collected in 0.1M PBS containing 15%
sucrose. Sections were treated in free-floating state until
the peroxidase-labeling step. After rinsing in 0.001% trypsin
in 50 mM Tris-HCl for 5 min and in 0.3% Triton X in
0.1 M PBS for overnight, sections were transferred to 2%
bovine albumin (Sigma Chemicals, St. Louis, MO, U.S.A.)
in 0.1 M PBS and incubated overnight at 4°C. Endogenous
peroxidase activity was blocked by 0.1% hydrogen per-
oxide and then in 0.1% phenylhydrazine (20 min, each).
For type I collagen labeling, sections were incubated
with polyclonal antibody against purified mouse type I
collagen (1:1,000; Chemicon International Inc., CA, U.S.A.)
for 48 h at 4 °C. After treating with secondary antisera
against mouse IgG (24 h, 4°C, 1:1000; Vector Laboratories,
Burlingame, CA, U.S.A.), avidin-biotin-peroxidase com-
plex method was applied (1 h, 25°C, 1:1000; Vector
Laboratories). The peroxidase label was developed in
0.04% 3,3-diamine-benzidine tetrahydrochloride (DAB)
with nickel enhancement (0.3% nickel ammonium sulfate inwere measured on the radiographs [see Fig. 1(e), (f)], and
were presented as mean mm±S.E.M.
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Control sections were incubated with (1) primary antibody
preabsorbed with purified mouse type I collagen and (2)
primary antibody replaced by non-specific mouse IgG.
Number of type I collagen-expressing chondrocytes was
counted within the defined field [see Fig. 4(b)] and was
presented as mean % (type I collagen-expressing cells/
total cells in the field)±S.E.M.
Recombinant OSF-1 was produced with the aid of
baculovirus in Spodopteria frugiperda and purified to
apparent homogeneity from the culture medium as
described previously11. Affinity-purified antibodies against
recombinant OSF-1 were produced as previously11, and
were verified in Western blotting11 in immunohisto-
chemistry12. Immunohistochemistry for OSF-1 followed the
procedures for the type I collagen immunolabeling.ELECTRONMICROSCOPY
To characterize the morphological changes of the articu-
lar chondrocytes, electronmicroscopy of the articular carti-
lage from proximal tibia was carried out. After fixation with
1% osmium tetroxide (1 h) and serial dehydration, the
cryostat sections (80 m) were embedded in epon medium
and coverslipped on siliconized glass slides. A small cube
of the epon medium (500 m×500 m×80m) was excised
from the sections, and ultra-thin sections (60 nm) were
made. After uranyl acetate and lead citrate treatment,
ultrastructure of the selected chondrocytes was studied bya transmission electronmicroscope (Hitachi H-500, Tokyo,
Japan).STATISTICAL ANALYSIS
Results were expressed as mean values±S.E.M.
Student’s t-test was employed to statistically evaluate the
Mineral apposition rate (MAR)10, Osteoid surface (OS)10
and Bone formation rate (BFR)10 in normal control group
and high Rac dose group. P value of less than 0.05 was
considered to be significant. To statistically evaluate the
Trabecular bone volume (BV/TV)10, articular cartilage area
and percentage of positive chondrocytes for OSF-1 and
type I collagen with respect to amount of Rac in the diet,
unpaired Student’s t-test was employed after confirming
the group independence by Analysis of Variance (ANOVA).
P value of less than 0.05 was considered to be significant.ResultsFig. 5. Proliferation of subchondral bone and atrophy of articular
cartilage. (a) Trabecular bone volume (BV/TV, %)10 increases in
parallel to the dose of given Rac. Bars represent the measured
values of 19.5±0.6 (%) for normal control group, 48.3±1.3 for
intermediate group, and 66.2±4.2 for the high dose group, respec-
tively. Articular cartilage area (m2) decreases in parallel to the
dose of given Rac. Bars represent the measured values of
144.2±3.5 (m2) for normal control group, 73.4±2.4 for intermedi-
ate group, and 45.9±3.9 for the high dose group, respectively.
After confirming the group independence by Analysis of variance
(ANOVA), unpaired Student’s t-test is used for statistical analysis
(*P<0.01).Fig. 6. Dynamic bone morphometry of subchondral bone. (a)
Mineral apposition rate. Bars represent 1.78±0.59 (m/day) for the
normal control group (NC) and 2.51±0.78 for the high Rac dose
group (Rac). (b) Osteoid surface (OS). Bars represent 18.03±1.79
(%) for the normal control group (NC) and 37.9±1.98 for the high
Rac dose group (Rac). (c) Bone formation rate (BFR). Bars
represent 169.2±72.3 (m3/m2m/year) for the normal control
group (NC) and 589.3±88.3 for the high Rac dose group (Rac).
Student’s t-test is used for statistical analysis (*P<0.01). All
parameters indicate that the subchondral bone formation is
significantly increased at 6-month time in the Rac-administrated
mice.ECTOPIC BONE FORMATION OF THE RETINYL ACETATE
(RAC)-TREATED ANIMALS
The contact radiography demonstrated prominent
ectopic bone formation in the animals receiving retinyl
acetate (Rac). Ectopic bone formation was at first localized
at the insertions of tendon and ligament, and then extended
along extension of the tendon and ligament (Fig. 1). In
order to measure the ossified lesion, longitudinal length of
the lesions in the Achilles (ac) and the suprapatellar (sp)
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radiographs [Figs 1(e), (f), 2].SUBCHONDRAL BONE PROLIFERATION AND CARTILAGE ATROPHY
Proliferation of bone tissue took place not only at the
insertions of tendon and ligament but also within the
subchondral region [Fig. 3(a), (b)]. The trabecular bone
volume (BV/TV, %)10 measured within a defined sub-
chondral field [Fig. 4(a), (b)] increased in parallel to the
doses of given Rac [Fig. 5(a)]. In the prominent cases, the
bone tissue occupied more than 70% of total volume within
the subchondral region [Fig. 5(a)]. Dynamic morphometry
at 6-month time further demonstrated that rate of bone
deposition in the subchondral bone was significantly
increased in the Rac-treated mice than in the normal
control mice (Fig. 6). Mineral apposition rate (MAS) is
1.78±0.59 (m/day) for the normal control group (NC) and
2.51±0.78 for the high Rac dose group (Rac). Osteoid
surface (MS) is 18.03±1.79 (%) for the normal control
group (NC) and 37.9±1.98 for the high Rac dose group
(Rac). Bone formation rate (BFR) is 169.2±72.3 (m3/
m2m/year) for the normal control group (NC) and
589.3±88.3 for the high Rac dose group (Rac). Osteoclast
surface [Oc.S/BS (%)], an indicator of osteoclastic activi-
ties10, was 5.43±0.9 (%) and 6.7±1.2 for the normal
control and high dose group mice, respectively (P=0.18).
Although statistical analysis failed to demonstrate signifi-
cant increase in osteoblastic activities, osteoblast surface
[Ob.S/BS (%)], an indicator of osteoblastic actives10, was
slightly increased from 10.4±3.6 (%) of the normal control
mice to 13.5±2.8 of the high dose group mice, respectively
(P=0.056). Taken together, the increased trabecular bone
volume [Fig. 5(a)] is supposed to result from increased
bone deposition (Fig. 6).The proliferation of subchondral bone took place in
parallel to the reduction of the mineralized and hyaline
cartilage [Fig. 3(c), (d)]. Histomorphometric measurement
of the hyaline cartilage [Fig. 4(a), (b)] demonstrated dose-
dependent reduction of the cartilage volume [Fig. 5(b)].
Close microscopic examination further suggested that the
bone-cartilage junction (also designed as osteochondral
junction) advanced toward the cartilage surface as if the
subchondral bone proliferated into the degenerating articu-
lar cartilage (Fig. 7). Double fluorescent labeling dis-
closed an increased bone deposition on the surface of
subchondral trabecular bone (arrowheads, Fig. 8 and
Fig. 6).DEGENERATIVE CHANGES IN THE ARTICULAR CARTILAGE
The most evident change in the articular cartilage of the
Rac-administrated mice was disappearance of mineralized
zone from the articular cartilage [Fig. 3(c), (d)]. This was
noted in all animals of the high Rac dose group (100%),
and 40% of the intermediate Rac dose group (8/total
20 animals). In order to address degenerative phenotypes
of the Rac-administrated chondrocytes, electron micro-
scopical study was carried out.
Three distinct phenotypes of the chondrocytes were
noted in the Rac-administrated mice, i.e., (1) chondrocytes
displaying myofibroblastic metaplasia within fibrocartilagi-
nous matrix [Fig. 9(a), (b)], (2) vacuolar (apoptotic)
chondrocytes with attendant matrix vesicles [Fig. 9(c)], and
(3) chondrocytes rich in glycogen granules [Fig. 9(d)].
These prominent changes in the phenotype of chondro-
cytes suggested subsequent alterations in the components
of cartilage matrix.Fig. 7. The osteochondral junction of the Rac-administrated animal. (a) Low magnification micrograph demonstrates numerous cartilage
fragments (arrowheads), which remained after chondrocytic chondrolysis. Rectangles b and d indicate the regions where corresponding
micrographs are demonstrated in (b) and (d). (b) Probable direction of bone proliferation (arrows). (c) Higher magnification of (b)
demonstrates a chondrocytic lacuna separated by a thin membrane of cartilage (rectangle). Shape of the bony protrusion resembles the
shape of the chondrocytic lacuna (double arrowheads). (d) Proliferating bone tissue occupies the chondrocytic lacuna (arrows).Fig. 8. Double fluorescent labeling of the subchondral bone.
Calcein labeling is performed twice with 7-day interval. (a) Double
strands are rarely seen in the subchondral bone of the normal
control mouse (normal control tibia, fluorescent micrograph,
bar=150 m). (b) Abundant double strands of the high Rac mouse
tibia indicating accelerated bone deposition (high Rac tibia,
fluorescent micrograph).ALTERED COMPONENTS OF CARTILAGE MATRIX
Normal articular chondrocytes produce type II collagen
as its major collagenous component but not type I collagen.
In human, only diseased chondrocytes like those of
osteoarthritis have been reported to express type I
collagen13–15. Thus, it is noteworthy that the affected
chondrocytes of the Rac-administrated mice expressed
type I collagen [Fig. 10(a), (b)]. While less than 1% of
chondrocytes expressed type I collagen in the normal
control animals, approximately 20% chondrocytes
expressed type I collagen in the Rac-administrated mice
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as on molecular interaction of type II collagen and other
molecules plays important roles in maintaining the struc-
tural integrity of articular cartilage16, the abnormal produc-
tion of type I collagen is likely to affect the structural
integrity of articular cartilage.
Epiphyseal cartilage is distinct from the normal articular
cartilage in that the epiphyseal cartilage provides the target
substrate for bone deposition. Osteoblast- stimulating
factor-1 (OSF-1) is one of the matrix molecules distinctively
expressed in the epiphyseal cartilage but not in the articular
cartilage12,17,18. In contrast to the clear absence of OSF-1
from the articular cartilage of the normal control ani-
mals [Fig, 10(c)], articular chondrocytes of the Rac-
administrated mice strongly expressed OSF-1 [Fig. 10(d)].
The abnormal expression of OSF-1 was noted in the
majority of the articular chondrocytes, and approximately
80% of cells expressed OSF-1 (Fig. 11).Fig. 9. Three distinct phenotypes of the articular chondrocytes. (a) Fibrocartilaginous metaplasia. Fibrocartilage is characterized by
intermingled collagen fibers (asterisks) and numerous myofibroblastic chondrocytes are noted (numbered from 1 to 5). oc: osteocytes within
the subchondral bone. (b) Myofibroblastic chondrocyte is characterized by prominent cell processes (arrowheads), numerous surface
vesicles (arrows, inset) and intracellular myofilaments (arrowheads, inset). (c) Vacuolar (apoptotic) chondrocytes in brood capsule
(numbered from 1 to 4). Numerous matrix vesicles are noted around the brood capsule (arrowheads). (d) Granular chondrocytes
characterized by rich glycogen granules. Bars: (a) 20 m, (b) 5 m, (b, inset) 0.5 m, (c) 15 m, (d) 15 m.Discussion
The skeletal changes associated with systemic retinoid
therapy reflect the influence of retinoids on the differentiat-
ing systems of bone. The well-documented changes of
bone include (1) progressive ossification of ligamentsand tendons, (2) premature fusion of epiphyses, and (3)
modeling abnormalities2,3. One important fact is that the
skeletal phenotypes of human differ considerably according
to the ages of patients suffering from hypervitaminosis A.
For instance, children (modeling bone) suffering from
hypervitaminosis A exhibit premature fusion of epiphysis
while adults (remodeling bone) exhibit ectopic ossification
of tendon2,3. These differences probably reflect variable
responses of the differentiating systems of bone at different
ages.
In contrast, involvements of the articular cartilage during
systemic retinoid therapy have not been addressed well.
Unlike ectopic ossification of tendons, degenerative
changes of cartilage may occur without the influence of
retinoids. Thus, it is possible that the influence of retinoids
on the degenerative cartilage disorders has been under-
estimated. According to our review of literature, there has
been only one reported case with destructive OA that is
apparently associated with the systemic retinoid therapy19.
The present study demonstrates that systemic admin-
istration of retinyl acetate, a clinically used synthetic deriva-
tive of vitamin A, causes profound effects on the articular
cartilage of laboratory animals.
Previous in vitro experiments have demonstrated that
the retinoid treatment of the cultured chondrocytes inhibits
974 M. Kubo et al.: Cartilage changes in retinyl acetate-administrated miceFig. 10. Ectopic expression of the functional molecules. (a) Type I
collagen is not expressed in the normal articular cartilage.
Asterisks indicate expression of type I collagen in the subchondral
bone, where type I collagen is the normal constituent. (b) Articular
cartilage of the high Rac dose animals prominently expresses type
I collagen (arrows). Bars: 50 m. (c) Normal articular cartilage
does not express OSF-1. (d) Majority of chondrocytes in the high
Rac dose animal expresses OSF-1 (arrowheads), and the expres-
sion remains in the partially resorbed cartilage matrices that are
incorporated in the subchondral bone (double arrowheads).Fig. 11. Increased expression of type I collagen and OSF-1
Percentage of the chondrocytes expressing type I collagen and
OSF-1 are presented as mean %+S.E.M. Bars represent the
measured values of 0.9±0.5 (%) and 1.8±1.1 for the type-I
collagen and OSF-1 expressing cells of normal control group,
6.4±2.3 and 34.5±3.9 for intermediate group, and 19.5±5.9 and
83.9±8.7 for the high dose group, respectively. Significantly higher
percentage of chondrocytes expresses both type I collagen and
OSF-1. After confirming the group independence by Analysis of
variance (ANOVA), unpaired Student’s t-test is used for statistical
analysis (*P<0.01).Fig. 12. A model for the articular phenotypes induced by systemic
retinoid administration. (a) The normal articular components and
their anatomical relation. (b) The retinoid-induced aberrant articu-
lar cartilage may lead to (1) chondrocytic chondrolysis that opens
the cartilage matrix for bone proliferation and/or (2) osteoblast
induction possibly mediated by cell-matrix interaction with type I
collagen and OSF-1.proteoglycan and mucopolysaccaride synthesis20,21. The
present study further demonstrates that the affected
chondrocytes produce abnormal fibrocartilage that is
normally seen during cartilage repair [Fig. 9(a)]. The fibro-cartilaginous matrix is not confined to the superficial zone
of cartilage, but is seen at all depth of the articular cartilage
including the deepest zone of osteochondral junction [Fig.
9(a)]. The extensive distribution of fibrocartilage suggests a
systemic influence of the retinoid rather than localized
cartilage repair confined at the cartilage surface. The
articular chondrocytes also display myofibroblastic meta-
plasia that is characterized by the diffuse intracellular
myofilament, prominent cell processes and abundant cell
surface vesicles [Fig. 9(b) and its inset]. Myofibroblasts
often accompanies an activated tissue repair and is nor-
mally seen adjacent to cartilage injury22,23. It should be
noted that the myofibroblasts also appear during systemic
administration of retinoid without evident cartilage injury.
Taken together, the systemic administration of retinoids
reproduces the cartilage phenotypes that resemble those
found during cartilage damage and repair. The detailed
examinations of osteochondral junction suggest that the
subchondral bone proliferates into the degenerating carti-
lage (Fig. 7). Despite careful examination, the present
study failed to demonstrate activated cartilage resorption
by the osteoclasts or macrophages (data not shown). In
turn, the matrix vesicle-derived lysosomal enzymes are
implicated in degradation of the cartilage matrix, a pro-
cess referred to as ‘chondrocytic chondrolysis’22,23. The
chondrocytic chondrolysis may facilitate opening-up of the
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chondral bone (Fig. 7). Furthermore, the mineral deposits
derived from the matrix vesicles may be pertinent to
subsequent mineralization of the newly synthesized
osteoid.
The remaining chondrocytes are often abundant in
glycogen granules, rough ER and Golgi apparatus, sug-
gesting an activated secretion of matrix molecules [Fig.
9(d)]. Chondrocytes in human OA often display the same
phenotype, and these chondrocytes are designated as
‘dummy cells’ because they do not secret type II collagen
but secrete type I collagen during their short life22,23. In
fact, the affected chondrocytes prominently express type I
collagen [Figs 10(a), (b) and 11]. Type I collagen provides
RGD-dependent signal that is capable of mediating cell
attachment of osteoblasts. A wide range of integrins, par-
ticularly that of 1 class, has been shown to be expressed
by osteoblasts24–26, and RGD-dependent integrin-binding
mediates cell-matrix interaction of the osteoblasts and
presumably transit signals for bone deposition24–26. In
addition to the matrix vesicle-derived minerals, the ectopic
type I collagen may also promote the subchondral bone
proliferation into the affected cartilage (Fig. 12).
Finally, the present study demonstrates that the affected
chondrocytes produces another functional molecule,
osteoblast-stimulating factor-1 (OSF-1). OSF-1 is a low
molecular weight matrix protein abundant in the epiphyseal
cartilage27,28. During endochondral ossification of rodents,
OSF-1 is localized in the epiphyseal cartilage12,17,18. While
disappearance of the epiphyseal cartilage during late teens
leads to cessation of bone growth in humans, epiphyseal
cartilage of rodents remains throughout life. However,
skeletal growth rate of rodents also declines after achieve-
ment of peak bone mass29. OSF-1 is abundant in the fetal
and young epiphyseal cartilage of rodents (20–15 g/g)
but is down-regulated in adult epiphyseal cartilage to
60 to 20-fold lower levels27,28. Thus, it is likely that
down-regulation of OSF-1 may be associated with the
physiological decline of growth rate in rodents.
OSF-1 in vitro has been shown to recruit osteoblast
progenitors12, and stimulates both mitotic (up to 1.8-fold in
DNA content) and osteoblastic activities (up to 2.0-fold in
alkaline phosphatase activity)30. Thus, OSF-1 within the
affected cartilage may also promote bone proliferation
(Fig. 12). On the other hand, because of the extensive
influence of retinoids on the differentiating systems of bone,
the affected chondrocytes may produce other aberrant
molecules. Further study on this line is warranted.
The extensive influence of retinoids on the differentiating
systems of bone has been well characterized in the field of
developmental biology. Retinoic acid has been found
endogenously in the regenerating amphibian limb and in
the developing chick limb bud, where 2.5-fold higher con-
centration of retinoic acid is localized on the posterior side
than on the anterior side31,32. The most striking report on
the limb morphogenesis is probably the transformation of
tails into legs in an Indian species of frog by local applica-
tion of retinoic acid33. Development of the joint structure is
characterized by its unique interface between articular
cartilage and subchondral bone, and probably depends on
the distinctive properties of articular cartilage not to allow
the subchondral bone to proliferate into the cartilage. The
terminal differentiation of chondrocytes is considered to be
essential to these properties, and type II collagen probably
plays the major role in maintaining the structural integrity of
articular cartilage16. De-differentiation of chondrocytes due
to the retinoid administration may lead to disturbance ofthese properties and thereby may lead to the abnormal
cartilage phenotypes observed in the present study.References
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